A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America

Abstract

Patients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent atherosclerotic cardiovascular disease (CVD) events. Dyslipidaemia, a major risk factor for CVD, is poorly controlled post ACS in countries outside Western Europe and North America, despite the availability of effective lipid-modifying therapies (LMTs) and guidelines governing their use. Recent guideline updates recommend that low-density lipoprotein cholesterol (LDL-C), the primary target for dyslipidaemia therapy, be reduced by C 50% and to \ 1.4 mmol/L (55 mg/dL) in patients at very high risk of CVD, including those with ACS. The high prevalence of CVD risk factors in some regions outside Western Europe and North America confers a higher risk of CVD on patients in these countries. ACS onset is often earlier in these patients, and they may be more challenging to treat. Other barriers to effective dyslipidaemia control include low awareness of the value of intensive lipid lowering in patients with ACS, physician non-adherence to guideline recommendations, and lack of efficacy of currently used LMTs. Lack of appropriate pathways to guide follow-up of patients with ACS post discharge and poor access to intensive medications are important factors limiting Digital Features To view digital features for this article go to

2022 Saudi Guidelines for the Management of Dyslipidemia

“…Ultimately, health-care expenditure and comprehensive oversight are difficult to streamline across these systems. [ 80 140 148 149 ]…”

Low-Density Lipoprotein Cholesterol Treatment Target Achievement in Patients with Myocardial Infarction, Percutaneous Coronary Intervention, or Stroke in Hong Kong

“…Despite the availability and affordability of statins, a large proportion of high risk individuals in Asia have low-density lipoprotein cholesterol (LDL-C) levels that remain above recommended treatment targets which contributes to the burden of atherosclerotic cardiovascular disease (ASCVD) [ 1 , 2 , 3 ]. Current guidelines from the American College of Cardiology/American Health Association and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) emphasize achieving an absolute LDL-C 1.8 mmol/L for people with ASCVD or who are at high risk of ASCVD events [ 4 , 5 ].…”